Implantable cardioverter defibrillator in nonischemic cardiomyopathy: A systematic review and meta‐analysis

The evidence to support implantable cardioverter defibrillator (ICD) in subjects with nonischemic cardiomyopathy (NICM) for primary prevention of sudden cardiac death (SCD) is not robust. This meta‐analysis intends to assess the impact of routine ICD implantation for primary prevention of mortality...

Full description

Saved in:
Bibliographic Details
Published inJournal of arrhythmia Vol. 34; no. 1; pp. 4 - 10
Main Authors Khan, Safi U., Ghimire, Subash, Talluri, Swapna, Rahman, Hammad, Khan, Muhammad U., Nasir, Fahad, Kaluski, Edo
Format Journal Article
LanguageEnglish
Published Japan John Wiley & Sons, Inc 01.02.2018
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN1880-4276
1883-2148
DOI10.1002/joa3.12017

Cover

More Information
Summary:The evidence to support implantable cardioverter defibrillator (ICD) in subjects with nonischemic cardiomyopathy (NICM) for primary prevention of sudden cardiac death (SCD) is not robust. This meta‐analysis intends to assess the impact of routine ICD implantation for primary prevention of mortality due to SCD in NICM based on all the published randomized clinical trials (RCTs). Six RCTs were selected using PubMed/Medline, EMBASE, and CENTRAL from inception to December 2016. Outcomes were calculated as random‐effects relative risk (RR) and risk difference (RD) with 95% confidence interval (CI). Patients were randomized to ICD arm and control arm (usual care, medical treatment, and anti‐arrhythmic drugs). ICD significantly reduced all‐cause mortality in NICM patients (RR, 0.74, 95% CI, 0.56‐0.97, P = .03, I2 = 40). Mortality benefit was achieved due to a significant reduction in sudden cardiac death (SCD) (RR, 0.47, 95% CI, 0.30‐0.73, P < .001, I2 = 0). There were no statistical differences between two groups with regard to risk of noncardiac mortality, non‐SCD, cardiac arrest, cardiac transplant, sustained ventricular tachycardia (VT), and VT requiring medical treatment. Our results support efficacy of ICDs at reducing all‐cause mortality due to a reduction in SCD.
Bibliography:ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1880-4276
1883-2148
DOI:10.1002/joa3.12017